Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:BVS NYSE:ENOV NASDAQ:LIVN NASDAQ:NVCR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$7.20+3.9%$6.96$5.81▼$14.38$595.29M0.84394,822 shs211,653 shsENOVEnovis$33.19+3.3%$29.68$25.47▼$49.83$1.90B1.681.18 million shs1.10 million shsLIVNLivaNova$55.91+2.5%$50.53$32.48▼$58.91$3.05B0.97695,049 shs555,644 shsNVCRNovoCure$13.00+2.4%$12.80$10.87▼$34.13$1.45B0.581.24 million shs1.42 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+1.32%-1.00%-3.48%+7.78%-39.05%ENOVEnovis-3.45%+5.41%+8.96%+4.76%-24.74%LIVNLivaNova-0.73%-3.52%+2.37%+20.72%+6.92%NVCRNovoCure+0.08%+3.93%+4.96%-24.46%-29.58%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBVSBioventus$7.20+3.9%$6.96$5.81▼$14.38$595.29M0.84394,822 shs211,653 shsENOVEnovis$33.19+3.3%$29.68$25.47▼$49.83$1.90B1.681.18 million shs1.10 million shsLIVNLivaNova$55.91+2.5%$50.53$32.48▼$58.91$3.05B0.97695,049 shs555,644 shsNVCRNovoCure$13.00+2.4%$12.80$10.87▼$34.13$1.45B0.581.24 million shs1.42 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBVSBioventus+1.32%-1.00%-3.48%+7.78%-39.05%ENOVEnovis-3.45%+5.41%+8.96%+4.76%-24.74%LIVNLivaNova-0.73%-3.52%+2.37%+20.72%+6.92%NVCRNovoCure+0.08%+3.93%+4.96%-24.46%-29.58%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBVSBioventus 2.75Moderate Buy$13.7590.97% UpsideENOVEnovis 3.00Buy$51.0053.66% UpsideLIVNLivaNova 2.86Moderate Buy$59.716.80% UpsideNVCRNovoCure 2.57Moderate Buy$28.79121.43% UpsideCurrent Analyst Ratings BreakdownLatest BVS, NVCR, LIVN, and ENOV Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025LIVNLivaNovaNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$64.008/21/2025LIVNLivaNovaBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$55.00 ➝ $58.008/8/2025ENOVEnovisCanaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$70.00 ➝ $58.008/8/2025ENOVEnovisUBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$65.00 ➝ $57.008/8/2025ENOVEnovisWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$48.00 ➝ $41.008/7/2025ENOVEnovisNeedham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$57.00 ➝ $49.007/25/2025NVCRNovoCureWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$40.00 ➝ $14.507/8/2025ENOVEnovisEvercore ISISubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$48.00 ➝ $46.007/8/2025NVCRNovoCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.007/7/2025BVSBioventusCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.006/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$34.00(Data available from 9/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBVSBioventus$564.14M1.06$0.57 per share12.58$2.80 per share2.57ENOVEnovis$2.11B0.90$19.18 per share1.73$45.10 per share0.74LIVNLivaNova$1.25B2.44$4.32 per share12.95$24.31 per share2.30NVCRNovoCure$605.22M2.40N/AN/A$3.33 per share3.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBVSBioventus-$156.23MN/AN/A15.65N/A-7.11%15.61%4.01%N/AENOVEnovis-$825.49M-$14.25N/A10.40N/A-37.80%6.78%3.73%11/5/2025 (Estimated)LIVNLivaNova$63.23M-$3.89N/A17.81N/A-16.13%14.57%6.91%10/29/2025 (Estimated)NVCRNovoCure-$168.63M-$1.56N/AN/AN/A-27.13%-47.74%-13.79%10/29/2025 (Estimated)Latest BVS, NVCR, LIVN, and ENOV EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025ENOVEnovis$0.74$0.79+$0.05-$0.64$555.80 million$564.50 million8/6/2025Q2 2025LIVNLivaNova$0.84$1.05+$0.21$0.50$332.20 million$352.50 million7/24/2025Q2 2025NVCRNovoCure-$0.39-$0.36+$0.03-$0.36$153.87 million$158.80 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBVSBioventusN/AN/AN/AN/AN/AENOVEnovisN/AN/AN/AN/AN/ALIVNLivaNovaN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBVSBioventus1.851.410.99ENOVEnovis0.532.251.15LIVNLivaNova0.311.291.09NVCRNovoCure0.281.451.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBVSBioventus62.94%ENOVEnovis98.45%LIVNLivaNova97.64%NVCRNovoCure84.61%Insider OwnershipCompanyInsider OwnershipBVSBioventus33.00%ENOVEnovis2.70%LIVNLivaNova0.29%NVCRNovoCure5.52%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBVSBioventus1,20082.68 million54.46 millionNot OptionableENOVEnovis7,36757.16 million55.62 millionOptionableLIVNLivaNova2,90054.60 million54.44 millionOptionableNVCRNovoCure1,488111.80 million105.63 millionOptionableBVS, NVCR, LIVN, and ENOV HeadlinesRecent News About These CompaniesUBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Boosts Holdings in NovoCure Limited $NVCRSeptember 17 at 3:08 AM | marketbeat.comNovoCure (NVCR) Gains Japan Approval For Optune Lua® In NSCLC Treatment ComboSeptember 16 at 9:37 PM | finance.yahoo.comNovocure earns Japanese approval for tumor-treating fieldsSeptember 15 at 1:32 PM | massdevice.comNovocure announces Japan MHLW approval for Optune LuaSeptember 15 at 1:32 PM | msn.comNovocure's Optune Lua® Receives Approval in Japan for the Treatment of Unresectable Advanced/Recurrent Non-Small Cell Lung Cancer (NSCLC)September 15 at 1:32 PM | tmcnet.comNovoCure Limited (NASDAQ:NVCR) Receives $28.79 Average PT from BrokeragesSeptember 15 at 3:11 AM | americanbankingnews.comNovoCure Limited (NASDAQ:NVCR) Given Consensus Rating of "Moderate Buy" by BrokeragesSeptember 14, 2025 | marketbeat.comTeza Capital Management LLC Cuts Holdings in NovoCure Limited $NVCRSeptember 12, 2025 | marketbeat.comInsider Spends US$997k Buying More Shares In NovoCureSeptember 11, 2025 | finance.yahoo.comNovoCure Limited (NVCR) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)September 10, 2025 | seekingalpha.comNovoCure (NASDAQ:NVCR) Shares Gap Up on Insider Buying ActivitySeptember 10, 2025 | marketbeat.comNovoCure (NASDAQ:NVCR) CEO Ashley Cordova Purchases 81,550 SharesSeptember 10, 2025 | marketbeat.comInsider Buying: NovoCure (NASDAQ:NVCR) CEO Buys 81,550 Shares of StockSeptember 9, 2025 | insidertrades.comCinctive Capital Management LP Sells 63,397 Shares of NovoCure Limited $NVCRSeptember 8, 2025 | marketbeat.comHsbc Holdings PLC Decreases Position in NovoCure Limited $NVCRSeptember 8, 2025 | marketbeat.comCubist Systematic Strategies LLC Sells 83,600 Shares of NovoCure Limited $NVCRSeptember 7, 2025 | marketbeat.comNovoCure Limited $NVCR Shares Purchased by Graham Capital Management L.P.September 7, 2025 | marketbeat.comPanagora Asset Management Inc. Sells 97,592 Shares of NovoCure Limited $NVCRSeptember 6, 2025 | marketbeat.comAmerican Century Companies Inc. Invests $1.26 Million in NovoCure Limited $NVCRSeptember 6, 2025 | marketbeat.comPalo Alto Investors LP Boosts Stock Holdings in NovoCure Limited $NVCRSeptember 4, 2025 | marketbeat.comFDA Fast-Track Cancer Treatments Drive Market Surge as Innovations AccelerateSeptember 2, 2025 | baystreet.caNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBVS, NVCR, LIVN, and ENOV Company DescriptionsBioventus NYSE:BVS$7.20 +0.27 (+3.90%) Closing price 04:00 PM EasternExtended Trading$7.19 -0.01 (-0.14%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Bioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Enovis NYSE:ENOV$33.19 +1.06 (+3.30%) Closing price 03:59 PM EasternExtended Trading$33.19 0.00 (0.00%) As of 06:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments. Its Prevention and Recovery segment offers orthopedic solutions and recovery sciences including rigid and soft orthopedic bracing, hot and cold therapy, bone growth stimulators, vascular therapy systems and compression garments, therapeutic shoes and inserts, electrical stimulators management, and physical therapy products which are used by orthopedic specialists, surgeons, primary care physicians, pain management specialists, physical therapists, podiatrists, chiropractors, athletic trainers, and other healthcare professionals. The company's Reconstructive segment operates surgical implant business, which includes a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and finger, as well as surgical productivity tools. The company distributes its products through independent distributors and directly under the ESAB and DJO brands. Enovis Corporation was formerly known as Colfax Corporation. The company was founded in 1995 and is headquartered in Wilmington, Delaware.LivaNova NASDAQ:LIVN$55.91 +1.38 (+2.53%) Closing price 04:00 PM EasternExtended Trading$55.90 -0.01 (-0.02%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, markets, and sells VNS Therapy System, an implantable pulse generator and connective lead that stimulates the vagus nerve; difficult-to-treat depression and drug-resistant epilepsy devices. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products. It serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. The company sells its products through direct sales representatives and independent distributors. LivaNova PLC was incorporated in 2015 and is headquartered in London, the United Kingdom.NovoCure NASDAQ:NVCR$13.00 +0.31 (+2.44%) Closing price 04:00 PM EasternExtended Trading$13.00 +0.01 (+0.04%) As of 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Fed Cut Rates: What Now for the S&P 500 and Equity Markets? Eli Lilly’s Oral GLP-1 Breakthrough Could Change Everything Bloom Energy Booms on AI Power Demand and Analyst Upgrades Can Apple’s iPhone 17 and AI Push Its Stock to New Highs? Why Seagate Is Wall Street's New Favorite AI Infrastructure Play New Catalysts Build Positive Pressure on Intel Stock Oracle to Hit $1 Trillion Valuation in 2025: Here’s Why General Mills Is a Generational Opportunity for Income Investors Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
